Amivantamab: Phase III MARIPOSA-2 combo vs chemotherapy in EGFR-mutated advanced NSCLC

MARIPOSA-2 study led by Antonio Passaro, MD found amivantamab combo reduced NSCLC progression by 56-52%, improving brain metastases treatment with manageable side effects.


By. Antonio Passaro, MD
Date. October 31, 2023

Antonio Passaro, MD, an oncologist specializing in lung cancer, has been deeply involved in the analysis and interpretation of the Phase 3 MARIPOSA-2 study. The primary objective of this pivotal trial was to investigate the efficacy and safety of the amivantamab regimen, in combination with chemotherapy, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations.

The study's key findings have been groundbreaking, revealing a significant advancement in the treatment landscape for NSCLC. Dr. Passaro highlights the remarkable results that demonstrate a 56% and 52% reduction in the risk of disease progression or death when utilizing amivantamab with or without lazertinib, combined with chemotherapy, in contrast to chemotherapy alone. These findings signify a substantial leap forward in managing NSCLC, particularly for patients with these specific EGFR mutations.

The implications of the MARIPOSA-2 study's outcomes are profound. The observed improvements in objective response rate (ORR), intracranial progression-free survival (PFS), and duration of response (DOR) associated with the amivantamab regimens underscore a significant benefit for patients. Notably, the data points to enhanced outcomes for patients, particularly those suffering from brain metastases, a historically challenging aspect of NSCLC treatment.

The impact of the MARIPOSA-2 study data on intracranial activity is transformative. The demonstrated efficacy of amivantamab in combination regimens offers a promising shift in the management of NSCLC, especially for patients with brain metastases. The ability of these regimens to address intracranial disease represents a critical advancement in the field of oncology.

Regarding safety, Dr. Passaro elucidates on the adverse events associated with amivantamab in combination with chemotherapy. While some hematologic adverse events, infusion-related reactions, and serious adverse events were observed, they were notably different from those seen with chemotherapy alone. Dr. Passaro stresses the importance of considering the overall risk-benefit profile and notes that the safety profile of the amivantamab regimen is manageable, with appropriate monitoring and intervention strategies in place.

Dr. Passaro's insights into the MARIPOSA-2 study outcomes underscore the remarkable progress in treating NSCLC, offering a more effective and tolerable therapeutic option for patients with specific EGFR mutations and brain metastases.